NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed?
In the first quarter of 2026, Beam Therapeutics Inc. reported a net loss of US$94.32 million, narrowing from US$108.33 million a year earlier, alongside a reduced basic loss per share from US$1.23 to US$0.91, while also sharing positive BEAM-302 clinical data supporting an accelerated FDA approval pathway.
What stands out is how Beam’s base-editing platform is translating into clinically meaningful signals in BEAM-302, reinforcing the company’s focus on precision genetic medicines across...